Different analogs of VIP, like VIPhyb (PAC1 antagonist) as well as (SN)VIPhyb (VPAC1 antagonist) and VIP-ALALA-E and VIP-LALA-E (VPAC1 agonists), are reported to inhibit various cancers [38], whereas Ro 25-1553 [39] and BAY 55-9837 (VPAC2 agonist) have been reported to be effective against bronchial asthma and insulin secretion, respectively [12]. This evidence concerns the gene VIP and cancer.